PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
289 / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.06%
Positive revenue growth while XRF.AX is negative. John Neff might see a notable competitive edge here.
28.92%
Positive gross profit growth while XRF.AX is negative. John Neff would see a clear operational edge over the competitor.
380.62%
Positive EBIT growth while XRF.AX is negative. John Neff might see a substantial edge in operational management.
380.62%
Positive operating income growth while XRF.AX is negative. John Neff might view this as a competitive edge in operations.
1164.40%
Net income growth above 1.5x XRF.AX's 13.78%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.99%
Share reduction while XRF.AX is at 1.21%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.42%
Positive OCF growth while XRF.AX is negative. John Neff would see this as a clear operational advantage vs. the competitor.
-360.42%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-74.99%
Negative 10Y revenue/share CAGR while XRF.AX stands at 151.40%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-42.26%
Negative 5Y CAGR while XRF.AX stands at 74.52%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-3.11%
Negative 3Y CAGR while XRF.AX stands at 49.22%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
145.92%
10Y OCF/share CAGR 1.25-1.5x XRF.AX's 132.15%. Bruce Berkowitz would confirm if the firm's long-term capital allocation yields better cash returns.
26672.25%
5Y OCF/share CAGR above 1.5x XRF.AX's 1139.05%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
184.38%
3Y OCF/share CAGR 1.25-1.5x XRF.AX's 144.47%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
110.42%
Net income/share CAGR at 50-75% of XRF.AX's 198.79%. Martin Whitman might question if the firm’s product or cost base lags behind.
14569.42%
5Y net income/share CAGR above 1.5x XRF.AX's 195.12%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
10.26%
Below 50% of XRF.AX's 72.97%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
479.91%
3Y equity/share CAGR above 1.5x XRF.AX's 30.57%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-56.88%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
12.80%
Inventory growth well above XRF.AX's 4.59%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
35.81%
Positive asset growth while XRF.AX is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
3.76%
Positive BV/share change while XRF.AX is negative. John Neff sees a clear edge over a competitor losing equity.
15122.66%
Debt growth far above XRF.AX's 35.08%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
92.32%
R&D growth of 92.32% while XRF.AX is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
-33.57%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.